Global Autism Spectrum Disorders Treatment Market Size Study & forecast, by Drug Class (Antipsychotic Drugs, SSRIs/Antidepressants, Stimulants, Other Drug Classes) by Type (Autistic Disorder, Asperger's Syndrome, Other Types), by Distribution Channel (Hos

Global Autism Spectrum Disorders Treatment Market Size Study & forecast, by Drug Class (Antipsychotic Drugs, SSRIs/Antidepressants, Stimulants, Other Drug Classes) by Type (Autistic Disorder, Asperger's Syndrome, Other Types), by Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies) and Regional Analysis, 2022-2029

Global Autism Spectrum Disorders Treatment Market is valued at approximately USD 1.85 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7.4% over the forecast period 2022-2029. Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that affects social interaction, communication, and behavior. It is called a spectrum disorder because the symptoms and severity can vary widely among individuals. ASD is typically diagnosed in early childhood, but sometimes it is not identified until later in life. Some common symptoms of ASD include difficulties with social interactions and communication, repetitive behaviors, and a strong focus on specific interests or topics. The key factor supporting the market growth is the rising burden of autism spectrum disorder (ASD) globally, growing awareness pertaining to ASD and rising number of investments, and the growing number of government initiatives such as forming various foundations and sanctioning different funding for the awareness of autism in various countries is anticipated to create the lucrative demand for the market during the forecast period.

However, Autism Spectrum Disorders Treatment Market Growth is driven by the rising prevalence of autism spectrum disorder (ASD) and the rising diagnostic rate of ASD. For instance, the World Health Organization (WHO) estimates that in March 2022, one in 100 children globally will have autism spectrum disorder. Early detection of ASD is essential to comprehending and managing the condition. According to numerous research, the average age of diagnosis is between 3 and 6 years old, with considerable variations depending on the socioeconomic level and ethnic origin. Additionally, rising R&D activity for advancements in autism spectrum disorder treatment, and new product development and product approvals are anticipated to create a lucrative opportunity for the market during the forecast period. However, the high cost of autism spectrum disorder treatment and diagnosis and stringent regulations pertaining to product approval stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Autism Spectrum Disorders Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players, the growing prevalence of autism disorder across the U.S., coupled with the growing adoption and uptake of therapies. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period, owing to factors such as rising demand for effective treatment. The development of healthcare infrastructure to fulfil the need for well-equipped healthcare institutions such as hospitals would create lucrative growth prospects for the Autism Spectrum Disorders Treatment market across the Asia Pacific region.

Major market player included in this report are:
Curemark, LLC (Rye, U.S.)
Alembic Pharmaceuticals Limited (Vadodara, India)
Yamo Pharmaceuticals (New York, U.S.)
PaxMedica, Inc. (Woodcliff Lake, U.S.)
F. Hoffmann-La Roche Ltd (Basel, Switzerland)
Aurobindo Pharma Ltd. (Hyderabad, India)
Otsuka Holdings Co. Ltd. (Tokyo, Japan)
Janssen Pharmaceuticals, Inc. (Titusville, New Jersey)
Teva Pharmaceutical Industries Ltd. (Tel Aviv, Israel)
H. Lundbeck A/S (Copenhagen, Denmark)

Recent Developments in the Market:
 In Oct. 2021, Axial Therapeutics reported that the FDA approved the company's Investigational New Drug (IND) application for its lead product, AB-2004, a molecular therapy that is being investigated for the treatment of irritability associated with ASD.
Global Autism Spectrum Disorders Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Class, Type, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:
Antipsychotic Drugs
SSRIs/Antidepressants
Stimulants
Other Drug Classes
By Type:
Autistic Disorder
Asperger's Syndrome
Other Types
By Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned
Curemark, LLC (Rye, U.S.)
Alembic Pharmaceuticals Limited (Vadodara, India)
Yamo Pharmaceuticals (New York, U.S.)
PaxMedica, Inc. (Woodcliff Lake, U.S.)
F. Hoffmann-La Roche Ltd (Basel, Switzerland)
Aurobindo Pharma Ltd. (Hyderabad, India)
Otsuka Holdings Co. Ltd. (Tokyo, Japan)
Janssen Pharmaceuticals, Inc. (Titusville, New Jersey)
Teva Pharmaceutical Industries Ltd. (Tel Aviv, Israel)
H. Lundbeck A/S (Copenhagen, Denmark)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.